ClinicalTrials.gg
CompletedNCT06774625Updated May 22, 2026

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

A Phase 2 interventional study of LTG-001 High Dose and LTG-001 Mid Dose in Acute Pain, Postoperative, sponsored by Latigo Biotherapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Latigo Biotherapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.

Enrollment
117th of 1,098
250 · median 76
Started
2024
with 63 others
Phase 2
121 of 1,180
9 open now
Registered
1,067th of 1,180
by date

Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 117th largest by enrollment of the 1,098 interventional ones that give a count, is one of 64 that started in 2024, is one of 121 in phase 2, and was the 1,067th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

198 more — sign in →

All 203 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,180 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are:

Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours?

Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain.

Participants will:

Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up.

Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain

03

Conditions studied

  • Acute Pain, Postoperative

Keywords

  • Acute Pain
  • Surgical Removal of Impacted Third Molars
  • Wisdom teeth
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged 18 to 50 years, inclusive, at the time of signing the
  • Has a body weight ≥ 45 kg and a ≤ 35 kg/m2.
  • Subject requires extraction of 2 or more third molars, two of which must be mandibular molars that must be fully or partially bony, or combination of one fully and one partially bony impaction.
  • Subject must agree to study required use of .
  • Post-surgical pain must meet protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Inability to take oral medications
  • Prior dental surgery within 60 days or other surgical history that could confound surgery or post-operative procedures.
  • History of impaired hepatic function or heart disease.
  • Abnormal liver laboratories or other lab abnormality indicative of serious medical condition.
  • Sensory abnormality that would confound post-surgery pain assessments.
  • Chronic use of NSAIDs, benzodiazepines, opioid use within the last year, use of medications that prolong , or other dietary and medication restrictions.
  • A subject with sleep apnea and/or on a home continuous positive airway pressure machine.
  • Positive drug screen.
  • Participant is under legal custodianship.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    LTG-001 High Dose

    High Dose

    Drug: LTG-001 High Dose

  • Experimental
    LTG-001 Mid Dose

    Medium Dose

    Drug: LTG-001 Mid Dose

  • Experimental
    LTG-001 Low Dose

    Low Dose

    Drug: LTG-001 Low Dose

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

  • Active comparator
    Suzetrigine

    Comparator

    Drug: Suzetrigine

Interventions

06

What researchers measure

Primary outcomes

  1. SPID 0-12

    Pain Intensity NRS Score change over the study.

    Time frame: 12 hours

Secondary outcomes

  1. Perceptible Pain Relief

    Time to Confirmed Perceptible Pain Relief, assessed via 2-stopwatch technique.

    Time frame: 12 hours

  2. Meaningful Pain Relief

    Time to Meaningful Pain Relief, assessed via 2-stopwatch technique.

    Time frame: 12 hours

  3. Time to Rescue

    Time to first use of rescue medication.

    Time frame: 12 hours

  4. TOTPAR over 0 to 12 hours

    Time-weighted summed pain relief as recorded on a sum of total pain relief (TOTPAR) over 0 to 12 hours (TOTPAR12) after the first dose of study drug.

    Time frame: 12 hours

  5. 2 Point Reduction in Pain on 0-10 Numerical Rating Scale

    Time to ≥ 2-point reduction in Numerical Rating Scale from baseline compared to placebo.

    Time frame: 12 hours

  6. Global Evaluation

    Subject's global evaluation based on a 5-point scale asking, "Overall, how effective do you think the study drug is as a treatment for pain?"

    Time frame: 12 hours

  7. No Required Rescue

    Subjects requiring no rescue opioid over 12 hours.

    Time frame: 12 hours

  8. Total Rescue

    Total opioid rescue consumption over 12 hours.

    Time frame: 12 hours

07

Study locations

1 site
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2025, 7 months.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 7 months is close to that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Jan 14, 2025
StartActual
Dec 19, 2024
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Results delay requested
May 15, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06774625
Lead sponsor
Latigo Biotherapeutics
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Dec 19, 2024
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Last update
May 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTG-001

Start the discussion